3.27
price down icon0.30%   -0.010
after-market アフターアワーズ: 3.35 0.08 +2.45%
loading
前日終値:
$3.28
開ける:
$3.23
24時間の取引高:
25,680
Relative Volume:
0.54
時価総額:
$35.20M
収益:
-
当期純損益:
$-15.16M
株価収益率:
-2.4746
EPS:
-1.3214
ネットキャッシュフロー:
$-13.65M
1週間 パフォーマンス:
-6.30%
1か月 パフォーマンス:
-13.26%
6か月 パフォーマンス:
-46.83%
1年 パフォーマンス:
+13.94%
1日の値動き範囲:
Value
$3.23
$3.3825
1週間の範囲:
Value
$3.04
$3.4499
52週間の値動き範囲:
Value
$2.74
$11.99

Lantern Pharma Inc Stock (LTRN) Company Profile

Name
名前
Lantern Pharma Inc
Name
セクター
Healthcare (1181)
Name
電話
972-277-1136
Name
住所
1920 MCKINNEY AVENUE, DALLAS, TX
Name
職員
21
Name
Twitter
@lanternpharma
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
LTRN's Discussions on Twitter

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-10-07 開始されました H.C. Wainwright Buy

Lantern Pharma Inc (LTRN) 最新ニュース

pulisher
08:00 AM

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board - StockTitan

08:00 AM
pulisher
06:17 AM

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Simply Wall St

06:17 AM
pulisher
Oct 31, 2024

Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine

Oct 31, 2024
pulisher
Oct 31, 2024

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace

Oct 31, 2024
pulisher
Oct 29, 2024

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com

Oct 29, 2024
pulisher
Oct 23, 2024

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire

Oct 23, 2024
pulisher
Oct 21, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire

Oct 21, 2024
pulisher
Oct 16, 2024

FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada

Oct 16, 2024
pulisher
Oct 15, 2024

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace

Oct 15, 2024
pulisher
Oct 15, 2024

FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive

Oct 15, 2024
pulisher
Oct 09, 2024

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com

Oct 09, 2024
pulisher
Sep 30, 2024

After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph

Sep 30, 2024
pulisher
Sep 26, 2024

11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex

Sep 26, 2024
pulisher
Sep 23, 2024

Lantern Pharma secures three new FDA rare disease tags - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - BioSpace

Sep 23, 2024
pulisher
Sep 23, 2024

Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch

Sep 23, 2024
pulisher
Sep 11, 2024

Norton Cancer Institute patient receives first-in-world clinical trial medicine dose - Norton Healthcare

Sep 11, 2024
pulisher
Aug 31, 2024

Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance

Aug 31, 2024
pulisher
Aug 28, 2024

NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma - OncLive

Aug 28, 2024
pulisher
Aug 27, 2024

11 Penny Stocks That Will Make You A Millionaire - Insider Monkey

Aug 27, 2024
pulisher
Aug 18, 2024

LTRN (Lantern Pharma) EPS (Basic) : $-1.65 (TTM As of Jun. 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 18, 2024

The Targeted Pulse: Apalutamide Provides a Faster, Deeper PSA Response vs Enzalutamide, Vorasidenib Receives Approval in Glioma, and More - Targeted Oncology

Aug 18, 2024
pulisher
Aug 18, 2024

Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update - Defense World

Aug 18, 2024
pulisher
Aug 17, 2024

LTRN (Lantern Pharma) 50-Day SMA : $4.42 (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

LTRN (Lantern Pharma) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 14, 2024

Q3 2024 Earnings Forecast for Lantern Pharma Inc. (NASDAQ:LTRN) Issued By Zacks Small Cap - Defense World

Aug 14, 2024
pulisher
Aug 12, 2024

LTRN: Second Quarter Results - Yahoo Finance

Aug 12, 2024
pulisher
Aug 11, 2024

The Targeted Pulse: The Practice-Changing Approval of Afami-cel for Advanced Synovial Sarcoma, Buprenorphine Offers Pain Relief for Bone Marrow Transplant, and More - Targeted Oncology

Aug 11, 2024
pulisher
Aug 10, 2024

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript - Seeking Alpha

Aug 10, 2024
pulisher
Aug 09, 2024

LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan

Aug 09, 2024
pulisher
Aug 08, 2024

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 - MSN

Aug 08, 2024
pulisher
Aug 08, 2024

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan

Aug 08, 2024
pulisher
Aug 07, 2024

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Business Wire

Aug 07, 2024
pulisher
Aug 07, 2024

Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday - Defense World

Aug 07, 2024
pulisher
Aug 06, 2024

LTRN: Harmonic Clinical Update - Zacks Small Cap Research

Aug 06, 2024
pulisher
Aug 05, 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Chronicle-Tribune

Aug 05, 2024
pulisher
Aug 01, 2024

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET - Business Wire

Aug 01, 2024
pulisher
Jul 20, 2024

Head-To-Head Analysis: Lantern Pharma (NASDAQ:LTRN) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World

Jul 20, 2024
pulisher
Jul 18, 2024

CASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial Comparison - American Banking and Market News

Jul 18, 2024
pulisher
Jul 17, 2024

Drug Repurposing Market Projected to Reach USD 47.8 Billion by 2034 with a CAGR of 4.7%Transparency Market Research - PR Newswire UK

Jul 17, 2024
pulisher
Jul 16, 2024

Study Shows First Evidence of Effective Systemic Therapy for HER2+ Breast Cancer With LM - Targeted Oncology

Jul 16, 2024
pulisher
Jul 15, 2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - Marketscreener.com

Jul 15, 2024
pulisher
Jul 15, 2024

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate - Yahoo Finance

Jul 15, 2024
pulisher
Jul 10, 2024

Kintara Therapeutics restructures share designations By Investing.com - Investing.com

Jul 10, 2024
pulisher
Jul 10, 2024

Cosmos Health completes hydrogel development for weight management By Investing.com - Investing.com India

Jul 10, 2024
pulisher
Jul 10, 2024

Netflix shares price target lifted on Q2 earnings report - Investing.com

Jul 10, 2024

Lantern Pharma Inc (LTRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):